Calamos Advisors LLC Sells 12,760 Shares of Novo Nordisk A/S $NVO

Calamos Advisors LLC trimmed its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 11.5% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 98,472 shares of the company’s stock after selling 12,760 shares during the period. Calamos Advisors LLC’s holdings in Novo Nordisk A/S were worth $3,619,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Loomis Sayles & Co. L P boosted its stake in shares of Novo Nordisk A/S by 6.0% in the 4th quarter. Loomis Sayles & Co. L P now owns 17,135,384 shares of the company’s stock worth $871,848,000 after buying an additional 969,916 shares during the last quarter. Franklin Resources Inc. increased its position in Novo Nordisk A/S by 5.1% during the fourth quarter. Franklin Resources Inc. now owns 14,702,508 shares of the company’s stock valued at $748,064,000 after acquiring an additional 717,719 shares during the last quarter. Morgan Stanley lifted its holdings in Novo Nordisk A/S by 3.5% in the fourth quarter. Morgan Stanley now owns 12,842,089 shares of the company’s stock valued at $653,406,000 after acquiring an additional 428,660 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in Novo Nordisk A/S by 99.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock valued at $492,940,000 after acquiring an additional 4,836,285 shares during the period. Finally, State Street Corp boosted its position in Novo Nordisk A/S by 1.0% in the third quarter. State Street Corp now owns 6,106,836 shares of the company’s stock worth $340,125,000 after purchasing an additional 59,153 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Sanford C. Bernstein began coverage on Novo Nordisk A/S in a research note on Wednesday, March 18th. They set an “outperform” rating and a $175.00 price target for the company. Weiss Ratings cut shares of Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, April 22nd. Nordea Equity Research raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Friday, June 19th. Zacks Research lowered shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research report on Monday. Finally, Citigroup reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, May 12th. Five investment analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $65.56.

Novo Nordisk A/S Stock Up 3.0%

NVO stock opened at $50.56 on Thursday. The business’s 50-day moving average price is $45.89 and its 200-day moving average price is $45.80. The stock has a market cap of $225.77 billion, a P/E ratio of 11.87, a PEG ratio of 4.48 and a beta of 0.77. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $71.79.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. The company had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. On average, equities research analysts forecast that Novo Nordisk A/S will post 3.38 EPS for the current year.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk won EU approval for its once-daily Wegovy pill, making it the first oral GLP-1 weight-loss treatment cleared across the European Union and expanding its obesity market reach. Novo Nordisk wins EU approval for Wegovy weight-loss pill
• Positive Sentiment: Novo Nordisk updated investors on a large Phase 3 heart failure-obesity study, suggesting continued pipeline progress in cardiometabolic disease, a major long-term growth area. Novo Nordisk Expands Cardiometabolic Reach With New Heart Failure–Obesity Trial
• Positive Sentiment: Fresh hemophilia trial results for Mim8/concizumab showed sustained efficacy and safety, expanding evidence for Novo’s rare blood disorder portfolio. Novo Nordisk (CPSE:NOVO B) Reports Fresh Hemophilia Trial Wins In Adults And Children
• Positive Sentiment: Novo Nordisk said most patients are choosing its obesity pill over Eli Lilly’s newer entrant, reinforcing confidence in its competitive position in the weight-loss drug market. It’s been three months since Lilly launched its obesity pill. Most people are taking Novo’s pill instead.
• Neutral Sentiment: Novo Nordisk also signed an agreement to evaluate a semaglutide implant, an early-stage move that adds optionality but is too preliminary to affect near-term results. Novo Nordisk signs pact to assess semaglutide implant
• Negative Sentiment: Sun Pharma won South Africa approval to launch a generic version of semaglutide, highlighting rising competitive pressure on Novo’s diabetes and obesity blockbusters. India’s Sun Pharma wins South Africa approval to launch generic Ozempic
• Negative Sentiment: Zacks Research downgraded Novo Nordisk to “strong sell,” which could weigh on sentiment despite the company’s positive operating news. Novo Nordisk A/S was downgraded by Zacks Research from “hold” to “strong sell”

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.